more_reports

Is This Pharma Co. the Next Eli Lilly?

  ()
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly.

Positive Phase 2 Clinical Trial Results Announced for Drug Treating Idiopathic Hypersomnia

  ()
Zevra Therapeutics Inc. (ZVRA:NASDAQ), a company specializing in rare disease therapeutics, has announced positive final results from its Phase 2 clinical trial evaluating the safety and tolerability of KP1077 for treating idiopathic hypersomnia.

Rare Disease Co. Presents Positive Phase 2 KP1077 Data

Research Report
  ()
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note.

Co. Targets More Verticals in Safe Supply

  ()
This Canadian firm, with a streaming business model, intends to invest in two additional segments of the safe supply ecosystem. Here, learn more about this approach to reducing harms from illegal drugs.

Co. Expands Telehealth Contract to New State

  ()
Reliq Health Technologies Inc. announced that a large U.S. health group has expanded its contract with the telehealth company to cover facilities in a new state. Read why one analyst thinks the stock is a Buy.

New Healthcare AI Partnership Aims to Transform Health Risk Assessments

  ()
Treatment.com AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector.

Pharma Co. Secures $650M Strategic Financing

Research Report
  ()
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine.

Pharma Stock Focuses on Successful Ensifentrine Launch

Research Report
  ()
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note.

New COPD Drug Slated for Approval Decision This June

  ()
Ahead of the upcoming PDUFA date, several analysts recommend the biopharma behind this treatment as a Buy. Read on to learn why.

Pharma Stock Nears FDA Approval

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval.

Investor Conference Highlights New Strategic Directions for Addressing Opioid Crisis

  ()
Safe Supply Streaming has provided an update on Safety Strips, its recent acquisition. Read on for more about how this impacts the company's battle against the opioid crisis.

Breakthrough COPD Treatment Awaits FDA Approval, Promising Major Market Impact

  ()
Verona Pharma is poised for a pivotal breakthrough with its drug candidate, ensifentrine, potentially transforming COPD treatment pending an upcoming FDA decision. Read on for more.

Critical Reforms Stuck in Congressional Gridlock

Contributed Opinion
  ()
McAlinden Research shares its thoughts on the current state of the cannabis market in light of recent legislative moves and two ETFs that may be impacted.
Tags: Cannabis

Medical School Renews Contract with Tech Co.

  ()
This move further validates the firm's Medical Education Suite. Discover why one analyst rates this healthcare-disrupting company as a Strong Buy.

Biotech Co. Positioned for Ensifentrine Approval, Analyst Says

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval.

Pharma's Promising Path in COPD Treatment

  ()
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock.

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

PDUFA Date Coming Up for U.K. Biopharma

Research Report
  ()
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.

Biopharma's New Drug for COPD Likely to be Approved

Research Report
  ()
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.

AI Healthcare Stock Has Bullish Setup, Expert Says

Contributed Opinion
  ()
Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy.

New AI Solutions Set To Transform Medical Education and Clinical Practice

  ()
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).

Analyst Says Pharma Co. Has No True Competitor

Research Report
  ()
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.